The OpGen Gene Panel product tests for causes of antimicrobial and antibiotic resistance in hospital patients. The FDA approval, CEO Oliver Schacht said, will help it move away from research and ...
San Francisco, USA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The Pan-Genomic and Multi-Gene Panel Testing Market reached a valuation of US$ 8,907.34 million in 2024 and is projected to grow steadily over the ...
We conducted a retrospective database analysis using medical and pharmacy claims data. Medicare Advantage Prescription Drug Plan members diagnosed with select malignant solid tumors were identified.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results